| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:FATP1-IN-1
CAS:1431945-95-7
Purity:98% HPLC LCMS Package:100mg;500mg;1g
|
| Company Name: |
Bide Pharmatech Ltd.
|
| Tel: |
400-1647117 13681763483 |
| Email: |
product02@bidepharm.com |
| Products Intro: |
Product Name:2-(4-(5-Fluoropyridin-2-yl)piperazin-1-yl)-N-(4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)acetamide
CAS:1431945-95-7
Purity:98% Package:1mg;5mg;10mg;25mg;50mg;100mg;250mg; Remarks:BD01466326
|
|
| | 1-Piperazineacetamide, 4-(5-fluoro-2-pyridinyl)-N-(4,5,6,7-tetrahydro-2-benzothiazolyl)- Basic information |
| Product Name: | 1-Piperazineacetamide, 4-(5-fluoro-2-pyridinyl)-N-(4,5,6,7-tetrahydro-2-benzothiazolyl)- | | Synonyms: | 1-Piperazineacetamide, 4-(5-fluoro-2-pyridinyl)-N-(4,5,6,7-tetrahydro-2-benzothiazolyl)-;FATP1-IN-1;FATP1 IN 1,FATP1IN1,FATP-1-IN-1;2-(4-(5-Fluoropyridin-2-yl)piperazin-1-yl)-N-(4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl)acetamide | | CAS: | 1431945-95-7 | | MF: | C18H22FN5OS | | MW: | 375.46 | | EINECS: | | | Product Categories: | | | Mol File: | 1431945-95-7.mol |  |
| | 1-Piperazineacetamide, 4-(5-fluoro-2-pyridinyl)-N-(4,5,6,7-tetrahydro-2-benzothiazolyl)- Chemical Properties |
| density | 1.349±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 62.5 mg/mL (166.46 mM; Need ultrasonic) | | pka | 8.76±0.20(Predicted) | | form | Solid | | color | Off-white to light yellow |
| | 1-Piperazineacetamide, 4-(5-fluoro-2-pyridinyl)-N-(4,5,6,7-tetrahydro-2-benzothiazolyl)- Usage And Synthesis |
| Biological Activity | FATP1-IN-1 is a fatty acid transport protein 1 (FATP1) inhibitor. FATP1-IN-1 is an inhibition of recombinant human or mouse acyl-CoA synthetase activity of FATP1, with the IC50 values of 0.046 μM or 0.60 μM, respectively[1].
FATP1-IN-1 (p.o.; 10 mg/kg) treatment shows the Cmax, AUC and Tmax were 5.5 μg/mL, 36 μg h/mL and 0.33 hours, respectively, and exceeds the mouse IC50 value of 0.22 μM without considering plasma protein binding. | | References | [1]. Matsufuji T, et al. Arylpiperazines as fatty acid transport protein 1 (FATP1) inhibitors with improved potency and pharmacokinetic properties. Bioorg Med Chem Lett. 2013;23(9):2560-2565. |
| | 1-Piperazineacetamide, 4-(5-fluoro-2-pyridinyl)-N-(4,5,6,7-tetrahydro-2-benzothiazolyl)- Preparation Products And Raw materials |
|